THERAPY DOSSIER · th-72f57314611c

Connexin43 mimetic peptide (Peptide5)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27629792 ↗2016Reported benefit

Systemic Administration of Connexin43 Mimetic Peptide Improves Functional Recovery after Traumatic Spinal Cord Injury in Adult Rats.

RatSpinal cord injuryContusionSprague-DawleyFemaleIntraperitonealImmediately and at 2 h and 4 h after injury

Model: Mild spinal cord contusion using the Multicentre Animal Spinal Cord Injury Study impactor

Systemic Peptide5 improved hindlimb locomotor function between 3 and 6 weeks, reduced at-level mechanical allodynia at weeks 1 and 6, lowered total and raised phosphorylated Connexin43 at 8 h, and reduced lesion size and glial reactivity while preserving neuronal numbers at 2 and 6 weeks.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…